• CAS No.:66357-35-5
Other grades of this product :
Ranitidine Basic information
Product Name:Ranitidine
Synonyms:(E)-N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine;1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-;1,1-ethenediamine,n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)eth;RANITIDINE;RANITIDINE BASE;TIMTEC-BB SBB006527;N’-Methyl-N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-2-nitro-1-ethenediarnine;Sostril
Product Categories:API;Active Pharmaceutical Ingredients;66357-35-5
Mol File:66357-35-5.mol
Ranitidine Chemical Properties
Melting point 69-70°C
Boiling point 437.1±45.0 °C(Predicted)
density 1.184±0.06 g/cm3(Predicted)
storage temp. Desiccate at +4°C
solubility H2O: 1.8 mg/mL
pkapKa 2.19±0.04 (Uncertain)
form solid
color tan
Water Solubility 24.7 mg/mL
CAS DataBase Reference66357-35-5(CAS DataBase Reference)
NIST Chemistry ReferenceRanitidine(66357-35-5)
EPA Substance Registry System1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- (66357-35-5)
Safety Information
Safety Statements 22-24/25
WGK Germany 2
RTECS KM6557000
Hazardous Substances Data66357-35-5(Hazardous Substances Data)
ToxicityLD50 oral in rat: > 5gm/kg
MSDS Information
Ranitidine hydrochloride English
Ranitidine Usage And Synthesis
DescriptionRanitidine, a H2-receptor agonist, caused contact dermatitis within the pharmaceutical industry.
UsesAntagonist (to histamine H2receptors).
UsesIt simultaneously reduces pepsin activity and is used for treating stomach and duodenum ulcers as well as other conditions accompanied by elevated acidity of the gastrointestinal tract. Synonyms of this drug are zantac, azantac, raniplex, ranidil, and others.
UsesRanitidine (cas# 66357-35-5) was used as a standard for testing the therapeutic effect of brown propolis extract against aspirin and ethanol- induced gastric ulcers.
IndicationsRanitidine (Zantac) is another H2 receptor antagonist that does not have the same antiandrogen side effects as cimetidine. Note that both cimetidine and ranitidine inhibit the cytochrome P-450 microsomal enzyme system.
Brand nameZantac (GlaxoSmithKline).
General DescriptionRanitidine, N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thiol] ethyl]-N'-methyl-2-nitro-l,1-ethenediamine (Zantac), is a white solid, which inits hydrochloride salt form is highly soluble in water. It is anaminoalkyl furan derivative with pKa values of 2.7 (sidechain) and 8.2 (dimethylamino). Ranitidine is more potentthan cimetidine, but less potent than famotidine. Likeother H2-antagonists, it does not appear to bind to otherreceptors.Bioavailability of an oral dose of ranitidine is about 50%and is not significantly affected by the presence of food.Some antacids may reduce ranitidine absorption and shouldnot be taken within 1 hour of administration of this drug. Theplasma half-life of the drug is 2 to 3 hours, and it is excretedalong with its metabolites in the urine. Three metabolites, ranitidineN-oxide, ranitidine S-oxide, and desmethyl ranitidine,have been identified. Ranitidine is only a weak inhibitor ofthe hepatic cytochrome isozymes, and recommended doses ofthe drug do not appear to inhibit the metabolism of otherdrugs. However, there have been isolated reports of drug interactions(warfarin, triazolam) that suggest that ranitidinemay affect the bioavailability of certain drugs by someunidentified mechanism, perhaps by pH-dependent effect onabsorption or a change in volume of distribution.In addition to being available in various dosage forms asthe hydrochloride salt, ranitidine is also available as a bismuthcitrate salt for use with the macrolide antibiotic clarithromycinin treating patients with an active duodenalulcer associated with H. pylori infection. Eradication of H.pylori reduces the risk of duodenal ulcer recurrence.
Biological ActivityPotent, selective and competitive histamine H 2 receptor antagonist (pA 2 = 6.95-7.2). In vivo, inhibits gastric acid secretion induced by histamine, pentagastrin, bethanecol and food. Also inhibits aspirin-induced gastric lesions.
Contact allergensRanitidine, an H2-receptor antagonist, can cause contact dermatitis within the pharmaceutical industry and in health care workers, or may induce systemic drug reactions in patients.
Clinical UseH2 antagonist: Conditions associated with hyperacidity
SynthesisRanitidine, N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]- N′-methyl-2-nitro-1,1-ethendiamine (16.2.8), is synthesized from furfuryl alcohol, which undergoes aminomethylation reaction using dimethylamine and paraform, which form 5- (dimethylaminomethyl)furfuryl alcohol (16.2.6). Further reaction with 2-mercaptoethylamine hydrochloride gives a product of substitution of the hydroxyl group in (16.2.6), 5-dimethylaminomethyl-2-(2′-aminoethyl)thiomethylfurane (16.2.7). Reacting this with Nmethyl- 1-methylthio-2-nitroethenaamine gives ranitidine (16.2.8).
Drug interactionsPotentially hazardous interactions with other drugs Alpha-blockers: effects of tolazoline antagonised. Antifungals: absorption of itraconazole and ketoconazole reduced; concentration of posaconazole possibly reduced - avoid. Antivirals: concentration of atazanavir reduced; concentration of raltegravir possibly increased - avoid; avoid for 12 hours before and 4 hours after rilpivirine. Ciclosporin: may increase or not change ciclosporin levels; nephrotoxicity, additive hepatotoxicity and thrombocytopenia reported. Cytotoxics: reduced gefitinib concentration; reduces concentration of erlotinib and possibly pazopanib, give at least 2 hours before or 10 hours after ranitidine; absorption of dasatinib reduced - avoid; possibly reduced absorption of lapatinib. Ulipristal: contraceptive effect possibly reduced - avoid with high dose ulipristal.
MetabolismRanitidine is not extensively metabolised. A small proportion of ranitidine is metabolised in the liver to the N-oxide, the S-oxide, and desmethylranitidine; the N-oxide is the major metabolite but accounts for only about 4-6% of a dose. The fraction of the dose recovered as metabolites is similar after both oral and IV dosing; and includes 6% of the dose in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and 1-2% as the furoic acid analogue. There is also some excretion in the faeces.
Dosage forms150 mg b.i.d.


Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873






Google translate: 日本语 한국어 Français Deutsch España Türkiye